The effect of financial conflicts of interest on voting behavior in US Food and Drug Administration (FDA) Advisory Committee meetings is frequently discussed, with research generally identifying small effects.1-3 This limited body of research justifies the FDA’s current approach to such conflicts. Members with conflicts of interest meeting the FDA’s criteria are excluded from meetings, unless “the need for the individual’s services outweighs the potential for a conflict of interest created by the financial interest involved.”4 In such cases, a waiver is issued, permitting participation in that meeting.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Lurie P. Suggestions for Improving Conflict of Interest Processes in the US Food and Drug Administration Advisory Committees—Past Imperfect. JAMA Intern Med. 2018;178(7):997–998. doi:10.1001/jamainternmed.2018.1324
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: